Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828353) titled 'A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).
Primary Sponsor: Regend Therapeutics
Condition:
COPD (Chronic Obstructive Pulmonary Disease)
Intervention:
Biological: Placebo
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 2026
Target Sample Size: 102
Countries of Recruitment:
China
To know more, visit https://clinicaltrial...